These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 31915116)

  • 1. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
    Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
    EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
    Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
    Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40.
    Zhang H; Wei P; Lv W; Han X; Yang J; Qin S; Zhang Y
    Cell Transplant; 2019 Dec; 28(1_suppl):37S-50S. PubMed ID: 31813279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
    Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
    J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
    Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway.
    Shi J; Yang C; An J; Hao D; Liu C; Liu J; Sun J; Jiang J
    J Exp Clin Cancer Res; 2021 Apr; 40(1):148. PubMed ID: 33931086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy.
    Chen JF; Wu P; Xia R; Yang J; Huo XY; Gu DY; Tang CJ; De W; Yang F
    Mol Cancer; 2018 Jan; 17(1):6. PubMed ID: 29329543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
    Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
    Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.
    Du T; Qu Y; Li J; Li H; Su L; Zhou Q; Yan M; Li C; Zhu Z; Liu B
    Mol Cancer; 2014 May; 13():100. PubMed ID: 24885567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway.
    Zhang XH; Li M; Kang YJ; Xie YQ; Cao YX
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6830-6838. PubMed ID: 31486482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.
    Xu X; Kong X; Liu T; Zhou L; Wu J; Fu J; Wang Y; Zhu M; Yao S; Ding Y; Ding L; Li R; Zhu X; Tang X; Zhang Y; Yang Q; Ling J; Zhou H
    Gynecol Oncol; 2019 Jul; 154(1):207-217. PubMed ID: 30979588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.
    Wang J; Wang Y; Shen F; Xu Y; Zhang Y; Zou X; Zhou J; Chen Y
    Cancer Med; 2018 Nov; 7(11):5665-5678. PubMed ID: 30334367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
    Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
    PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E2F1-EP300 co-activator complex potentiates immune escape in nasopharyngeal carcinoma through the mediation of MELK.
    Wang Q; Yu Q; Liu Y
    Histol Histopathol; 2024 Apr; 39(4):511-523. PubMed ID: 37728155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.
    Lv Z; Wang M; Hou H; Tang G; Xu H; Wang X; Li Y; Wang J; Liu M
    Int J Biol Sci; 2023; 19(11):3293-3306. PubMed ID: 37496990
    [No Abstract]   [Full Text] [Related]  

  • 17. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling.
    Lin Y; Chen X; Lin L; Xu B; Zhu X; Lin X
    Cell Mol Biol Lett; 2024 May; 29(1):63. PubMed ID: 38698330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. xCT contributes to colorectal cancer tumorigenesis through upregulation of the MELK oncogene and activation of the AKT/mTOR cascade.
    Tang B; Zhu J; Liu F; Ding J; Wang Y; Fang S; Zheng L; Qiu R; Chen M; Shu G; Xu M; Lu C; Zhao Z; Yang Y; Ji J
    Cell Death Dis; 2022 Apr; 13(4):373. PubMed ID: 35440604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
    Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
    Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
    Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
    Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.